<DOC>
	<DOCNO>NCT00533533</DOCNO>
	<brief_summary>Gastric cancer common malignancy Korea . The prognosis unresectable gastric cancer improve cytotoxic chemotherapy , median survival rarely exceed 1 year . New agent taxane , irinotecan oxaliplatin combine old agent 5-FU without leucovorin , doxorubicin , cisplatin show high response rate phase II study . Docetaxel single agent show response rate 17-24 % , combination docetaxel cisplatin show response rate 37-56 % overall survival 9-10.4 month . Oxaliplatin combination 5-FU leucovorin ( FOLFOX-6 ) show objective response rate 50 % , include 4 % complete response . The preclinical study , oxaliplatin show additive synergistic cytotoxic property fluoropyrimidines , thymidylate synthase inhibitor , topoisomerase I inhibitor , microtubule inhibitor DNA modifying/alkylating agent . The combination docetaxel oxaliplatin study previously phase I set patient metastatic breast non-small cell lung cancer . The combination docetaxel oxaliplatin feasible well tolerated regimen . Recommended dose 75mg/m2 docetaxel day 1 70mg/m2 oxaliplatin day 2 without G-CSF support . The aim trial determine dose limit toxicity , maximum tolerate dose ( MTD ) efficacy oxaliplatin docetaxel combination chemotherapy patient advance gastric cancer .</brief_summary>
	<brief_title>A Phase I/II Trial Docetaxel Oxaliplatin Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>Primary objective : To define dose-limiting toxicity maximum tolerate dose phase I study To evaluate overall response rate phase II study Secondary objective : 1 . To evaluate safety tolerability treatment combination . 2 . To estimate overall survival . 3 . To estimate time progression duration overall response .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically document gastric adenocarcinoma include adenocarcinoma esophagogastric junction 18 ≤ age ≤ 70 ECOG performance status 0 2 At least one definite measurable lesion ( ) : ≥ 1 cm spiral CT scan ≥ 2 cm physical examination Previously untreated metastatic gastric cancer patient relapse gastric cancer patient ( patient recurrence least 6 month date last administration adjuvant chemotherapy and/or radiation therapy 5FU and/or leucovorin contain regimen include study ) Written inform consent Minimum life expectancy 12 week Adequate liver , renal , bone marrow function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; ASAT and/or ALAT &lt; 3 UNL ; serum creatinine ≤ 1.5 ULN Any malignancy within past 5 year except skin basal cell cancer CIS cervix Serious comorbid diseases Pregnancy lactation Previous history drug allergy one drug study regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Docetaxel , Oxaliplatin</keyword>
	<keyword>Phase I/II study</keyword>
	<keyword>Advanced gastric cancer</keyword>
	<keyword>First line treatment</keyword>
	<keyword>Advanced gastric cancer measurable disease</keyword>
</DOC>